Including Use Of Radioactive Properties Patents (Class 436/57)
-
Patent number: 6291189Abstract: The present invention provides methods whereby the positions of peptide amide groups that are labeled with a heavy hydrogen in a polypeptide or protein can be localized at high resolution. The methods are useful for determining which peptide amide groups in a polypeptide or protein are accessible to solvent, mapping the binding site and/or binding surface of a binding protein, and/or studying allosteric or other conformational changes in a polypeptide or protein which alter the rates at which certain peptide amide hydrogens exchange with solvent.Type: GrantFiled: August 19, 1997Date of Patent: September 18, 2001Assignee: Carta Proteomics, Inc.Inventor: Virgil L. Woods, Jr.
-
Patent number: 6284475Abstract: The present invention provides methods for diagnosing and/or monitoring thrombophilic disease in a patient that can result from the antiphospholipid antibody syndrome (aPL syndrome). The methods of the invention are premised on the inhibition of binding of an anticoagulant protein, annexin, preferably annexin-V, to phospholipids by antiphospholipid (aPL) antibodies in a patient blood sample.Type: GrantFiled: July 10, 1998Date of Patent: September 4, 2001Assignee: Mount Sinai School of Medicine of the City of New YorkInventor: Jacob H. Rand
-
Publication number: 20010006619Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.Type: ApplicationFiled: January 5, 2001Publication date: July 5, 2001Applicant: RESEARCH CORPORATION TECHNOLOGIES, INC.Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
-
Patent number: 6228651Abstract: A process for the preparation of an analytical sample characterized by depositing and separating solely the impurity to be analyzed from phosphoric acid; a process for analysis of the impurity characterized by depositing and separating solely the impurity from phosphoric acid and applying the separated material to analysis; a process for preparation of high grade phosphoric acid characterized by depositing and separating solely the impurity from phosphoric acid to be purified; a process for the fabrication of a semiconductor device characterized by using phosphoric acid, the impurity content of which is not more than 10−3 Bq/mL, defined by the concentration of a contained radioactive element selected from the group consisting of Pb, Bi and Po, as a processing solution.Type: GrantFiled: December 30, 1998Date of Patent: May 8, 2001Assignee: Fujitsu LimitedInventors: Hiroyuki Fukuda, Takashi Nakanishi, Mitsuru Hirose
-
Patent number: 6207111Abstract: A system for describing the physical distribution of an agent that accumulates selectively in tissue of a patient in an excised surgical specimen. The system comprises an agent which selectively concentrates in a cancer or precancer or focus of infection or other pathological condition. The system comprises a detector sensitive to the agent which is present in the surgical specimen. The system also comprises an apparatus capable of forming an image based on the information gathered by the detector, and which image describes the physical distribution of the agent in the surgical specimen so that a surgeon can be guided by the image provided by the apparatus, said apparatus connected to said detector.Type: GrantFiled: December 31, 1997Date of Patent: March 27, 2001Assignee: PEM Technologies, Inc.Inventor: Irving N. Weinberg
-
Patent number: 6197278Abstract: A method of imaging apoptosis in vivo, using radiolabeled annexin, is described.Type: GrantFiled: April 29, 1998Date of Patent: March 6, 2001Assignees: The Board of Trustees of the Leland Stanford Junior University, University of WashingtonInventors: Francis G. Blankenberg, H. William Strauss, Jonathan F. Tait, Peter D. Katsikis
-
Patent number: 6159427Abstract: A method and apparatus for in-line tritium-in-water monitoring in which a sample of water is vaporized at a temperature sufficient to transform it to dry water vapor substantially free of liquid water droplets. The water vapor is transferred to a tritium detection device having a chamber heated to a temperature at which there is substantially no condensation of the water vapor, the detection device comprising volume detection device adapted to detect .beta.-decay of tritium atoms in the water vapor. The volume detection device may comprise ionization chamber detector, gas scintillation counting detector and gas electron multiplier detector. The method and apparatus are preferably used to detect leaks of tritiated water from the primary to secondary side of the heat transport systems associated with certain types of nuclear reactors, and when used on an in-line, continuous basis, provide a time response as low as 10 seconds with the detection limits depending on the type of volume detection equipment used.Type: GrantFiled: April 19, 1999Date of Patent: December 12, 2000Assignee: Ontario Power Generation Inc.Inventor: Nazir P. Kherani
-
Patent number: 6132981Abstract: The present invention is directed to a method for detecting a mammal's prior exposure to radiation or radiomimetic agents. Labeled antibodies are employed to determine the quantity of transferrin receptors on the red blood cells of the mammal. The quantity of transferrin receptors on the red blood cells of the mammal is correlated to the mammal's prior exposure.Type: GrantFiled: October 27, 1997Date of Patent: October 17, 2000Assignee: The Research Foundation of State University of New YorkInventors: Joseph K. Gong, Chester A. Glomski
-
Patent number: 6126901Abstract: An apparatus and method for detecting low levels of one or more radionuclides in a fluid sample uses a substrate that includes an ion exchange resin or other sorbent material to collect the radionuclides. A collecting apparatus includes a collecting chamber that exposes the substrate to a measured amount of the fluid sample such that radionuclides in the fluid sample are collected by the ion exchange resin. A drying apparatus, which can include a drying chamber, then dries the substrate. A measuring apparatus measures emissions from radionuclides collected on the substrate. The substrate is positioned in a measuring chamber proximate to a detector, which provides a signal in response to emissions from the radionuclides. Other analysis methods can be used to detect non-radioactive analytes, which can be collected with other types of sorbent materials.Type: GrantFiled: July 29, 1997Date of Patent: October 3, 2000Assignee: Thermo Power CorporationInventors: Keith D. Patch, Dean T. Morgan
-
Patent number: 6103533Abstract: A method of identifying individual substances within a mixture of substances comprises causing the mixture to travel past a spaced series of detectors, each being arranged to produce a signal representative of a characteristic of the mixture as it passes, repeatedly measuring the signals from each detector at a plurality of times, transforming into velocity space, and identifying individual substances within the mixture according to the peaks they create in velocity space.Type: GrantFiled: March 26, 1998Date of Patent: August 15, 2000Assignee: Imperial College of Science, Technology and MedicineInventors: John Francis Hassard, David John Colling
-
Patent number: 6060321Abstract: A disposable ultraviolet dosimeter for rapid visual estimation of cumulative exposure to UV-A and UV-B radiation.Type: GrantFiled: July 6, 1998Date of Patent: May 9, 2000Inventor: George B. Hovorka
-
Patent number: 6046012Abstract: This disclosure relates to novel antibodies specific to the recently discovered receptor to human interleukin 12 (IL-12R). The antibodies to IL-12R, most preferably, the monoclonal antibodies to that protein, are useful in determining the status of the human immune system and as diagnostic reagents or potential therapeutic reagents for conditions involving imbalances in IL-12 levels or cell types sensitive to IL-12 activation.Further aspects of the disclosure relate to methods of producing and purifying such novel antibodies and hybridoma cell lines capable of their production. Another aspect of the disclosure relates to an immunoprecipitation assay for the detection of solubilized IL-12R which employs, in a preferred embodiment, monoclonal antibodies to the receptor of the present invention covalently bound to Protein G-Sepharose resin.Type: GrantFiled: January 27, 1997Date of Patent: April 4, 2000Assignee: Hoffmann-La Roche Inc.Inventors: Richard Anthony Chizzonite, Theresa Patricia Truitt
-
Patent number: 6043486Abstract: A concentration measurement device is calibrated for a target element by performing a concentration measurement on a reference standard sample which includes a number of atoms of a radioactive marker element in known ratio to a number of atoms of the target element. Both the ratio of atoms of the target element to those of the radioactive marker element and a count of decay products of the radioactive marker element are analytically quantified. Because the count of decay products is correlated with the number of atoms of the radioactive marker element, the ratio and the count of decay products are used to accurately calculate the otherwise unknown number of impurity atoms and to calibrate a concentration measurement signal from the concentration measurement device.Type: GrantFiled: January 5, 1999Date of Patent: March 28, 2000Assignee: Advanced Micro Devices, Inc.Inventor: Tim Z. Hossain
-
Patent number: 6025336Abstract: Persistent biological indicators of exposure to ionizing radiation, particularly nucleic acid indicators, can be employed in determining whether a subject has been exposed to ionizing radiation. Such biological indicators can be identified via the technique of differential display.Type: GrantFiled: February 15, 1996Date of Patent: February 15, 2000Assignee: University of PittsburghInventors: Kristin L. Goltry, Joel S. Greenberger
-
Patent number: 5993777Abstract: The present invention relates to a class of compounds having affinity for certain cancer cells, e.g. lung carcinomas, colon carcinomas, renal carcinomas, prostate carcinomas, breast carcinomas, malignant melanomas, gliomas, neuroblastomas and pheochromocytomas. The compounds of the present invention can also bind with high specificity to cell surface sigma receptors and can therefore be used for diagnostic imaging of any tissue having an abundance of cells with sigma receptors. The present invention provides such compounds as agents for diagnostic imaging and for detecting and treating tumors containing the cancer cells described above.Type: GrantFiled: June 6, 1995Date of Patent: November 30, 1999Assignee: Research Corporation Technologies, Inc.Inventors: Christy S. John, Jesse Baumgold, John G. McAfee, Terry Moody, Wayne Bowen
-
Patent number: 5993664Abstract: A method for producing a material for heavy metal absorption or for analytically detecting heavy metals, especially uranium and radium, comprises the steps of: providing a material containing nitrogen which is organically bonded in a polymer; treating said material with potassium permanganate in an alkaline solution; and treating the material with iron(II) hydroxide in an alkaline solution. The material produced in this way is suitable for being used for a method of analytically detecting heavy metals and heavy metal istopes in a sample liquid as well as for a method of cleaning contaminated liquids.Type: GrantFiled: July 21, 1997Date of Patent: November 30, 1999Assignee: Thomas StreilInventors: Thomas Streil, Wolfram Grundke, Gunther Just
-
Patent number: 5912178Abstract: Methods and apparatus are disclosed for determining the presence of a catabolic state in an organism (or collection of organisms) by measuring changes in isotopic ratios in biological materials obtained from them. Preferably, .sup.13 C/.sup.12 C ratios are monitored for isotopically unenriched animals, such as by testing changes in the ratio in blood or breath.Type: GrantFiled: February 16, 1994Date of Patent: June 15, 1999Assignee: Wisconsin Alumni Research FoundationInventors: Warren P. Porter, Isabel W. Treichel, Mark E. Cook
-
Patent number: 5900377Abstract: Disclosed is a method for separating leukocytes from platelets. Blood serum is added to a centrifuge tube. A suspension containing leukocytes and platelets is then added to form a layer on top of the blood serum, the layer having a density less than the density of the blood serum. The cells and the layers are centrifuged at a force and for a time sufficient to separate the leukocytes from the platelets. The resulting, isolated leukocytes are then recovered from the centrifuge tube. In some embodiments, a suspension of the leukocyte cells are pretreated by incubating with a stannous ion reducing agent, the suspension having a stannous ion concentration of from about 50 .mu.g to about 1000 .mu.g stannous ion per 10.sup.8 leukocyte cells. A suspension of the pretreated leukocyte cells is then incubated with a solution containing a technetium-99m (VII) salt, preferably sodium .sup.99m Tc-pertechnetate, to radiolabel the leukocyte cells.Type: GrantFiled: March 3, 1997Date of Patent: May 4, 1999Assignee: Syncor International CorporationInventors: Paul Richard Gotti, Trenton Todd Rees
-
Patent number: 5876671Abstract: A standard laboratory module for automatically producing a solution of cominants from a soil sample. A sonication tip agitates a solution containing the soil sample in a beaker while a stepper motor rotates the sample. An aspirator tube, connected to a vacuum, draws the upper layer of solution from the beaker through a filter and into another beaker. This beaker can thereafter be removed for analysis of the solution. The standard laboratory module encloses an embedded controller providing process control, status feedback information and maintenance procedures for the equipment and operations within the standard laboratory module.Type: GrantFiled: May 30, 1995Date of Patent: March 2, 1999Assignee: The Regents of the University of California office of Technology TransferInventors: Tony Beugelsdijk, Robert M. Hollen, Tracy H. Erkkila, Lawrence E. Bronisz, Jeffrey E. Roybal, Michael Leon Clark
-
Patent number: 5872008Abstract: A method for diagnosing premenstrual syndrome in a female human comprising the step of measuring the ratio of esterified L-carnitine to free L-carnitine in a patient's serun or plasma. Women who have an esterified to free L-carnitine ratio of greater than about 0.22 are diagnosed as having premenstrual syndrome.Type: GrantFiled: February 9, 1996Date of Patent: February 16, 1999Inventors: Glenn O. Bair, Austin Shug
-
Patent number: 5854080Abstract: A process and apparatus for separating tritium from an aqueous solution that contains one or more additional dissolved radionuclides is disclosed. In accordance with the process the aqueous solution as a first liquid phase is contacted with each of three layers as a solid phase within a column. A first layer comprises particles having a plurality of pendent methylene diphosphonate groups. A second layer comprises strongly basic anion exchange particles, and a third layer comprises polymer particles free of ionically charged groups. The contact is maintained until a second liquid phase is formed that contains tritium as substantially the only radionuclide, and that second liquid phase is collected and can then be counted to determine the amount of tritium present. The column with its three layers constitutes the separation apparatus.Type: GrantFiled: June 26, 1997Date of Patent: December 29, 1998Assignee: Eichrom Industries, Inc.Inventor: James Travis Harvey
-
Patent number: 5843784Abstract: To permit detection of trace unstable reaction products to clarify the reaction process of oxygenation, this invenion provides a method of introducing positron nuclide .sup.15 O as an oxygen additive into the reaction system.Type: GrantFiled: September 13, 1996Date of Patent: December 1, 1998Assignee: Research Development Corporation of JapanInventors: Yasuyoshi Watanabe, Bengt Langstrom
-
Patent number: 5811072Abstract: Additives are proposed for compositions comprising radiolabelled organic compounds e.g. 32P-labelled nucleotides. Stabilisers are selected from tryptophan, para-aminobenzoate, indoleacetate and the azole group. Dyes are selected from Sulphorhodamine B, Xylene Cyanol, Azocarmine B and New Coccine. Preferred compositions contain both stabiliser and dye.Type: GrantFiled: May 6, 1997Date of Patent: September 22, 1998Assignee: Amersham Pharmacia Biotech UK LimitedInventors: Roger Malcolm Price, Christopher Charles May, Elizabeth Margaret Buckley, Timothy Stone
-
Patent number: 5691157Abstract: The present invention is directed to a method for detecting a mammal's prior exposure to radiation or radiomimetic agents. Labeled antibodies are employed to determine the quantity of transferrin receptors on the red blood cells of the mammal. The quantity of transferrin receptors on the red blood cells of the mammal is correlated to the mammal's prior exposure.Type: GrantFiled: October 24, 1995Date of Patent: November 25, 1997Assignee: The Research Foundation of State University of New YorkInventors: Joseph K. Gong, Chester A. Glomski
-
Patent number: 5686058Abstract: Additives are proposed for compositions comprising radiolabelled organic compounds e.g. 32P-labelled nucleotides. Stabilizers are selected from tryptophan, para-aminobenzoate, indoleacetate and the azole group. Dyes are selected from Sulphorhodamine B, Xylene Cyanol, Azocarmine B and New Coccine. Preferred compositions contain both stabilizer and dye.Type: GrantFiled: June 6, 1995Date of Patent: November 11, 1997Assignee: Amersham International plcInventors: Roger Malcolm Price, Christopher Charles May, Elizabeth Margaret Buckley, Timothy Stone
-
Patent number: 5677189Abstract: A method of detecting sphingosines and platelet activation is disclosed.Type: GrantFiled: June 29, 1995Date of Patent: October 14, 1997Assignee: Oncomembrane, Inc.Inventors: Yasuyuki Igarashi, Yutaka Yatomi, Hideki Ohta, Sen-Itiroh Hakomori
-
Patent number: 5667763Abstract: Additives are proposed for compositions comprising radiolabelled organic compounds e.g. 32P-labelled nucleotides. Stabilizers are selected from tryptophan, para-aminobenzoate, indoleacetate and the azole group. Dyes are selected from Sulphorhodamine B, Xylene Cyanol, Azocarmine B and New Coccine. Preferred compositions contain both stabilizer and dye.Type: GrantFiled: June 19, 1996Date of Patent: September 16, 1997Assignee: Amersham International plcInventors: Roger Malcolm Price, Christopher Charles May, Elizabeth Margaret Buckley, Timothy Stone
-
Patent number: 5658739Abstract: The binding sites of binding proteins and their binding partners are characterized, at the individual amino acid level, by a combination of tritium exchange labeling and sequential degradation and analysis of tritiated fragments under slowed exchange conditions.Type: GrantFiled: May 10, 1994Date of Patent: August 19, 1997Assignee: The Regents of the University of CaliforniaInventor: Virgil L. Woods, Jr.
-
Patent number: 5648268Abstract: The present invention is directed to an analytic method for detecting trace elements in fluid solution. A cation exchange resin is packed with a radiolabelled exchange material having certain characteristics and replaces the trace element ions in the fluid which becomes labelled. The label is subsequently detected using sensitive and well known radiation detection methods.Type: GrantFiled: December 6, 1994Date of Patent: July 15, 1997Assignee: IBM CorporationInventors: John Samuel Batchelder, Philip Charles Danby Hobbs, Miro Plechaty, Keith Randal Pope
-
Patent number: 5643728Abstract: A method of marking a liquid and subsequently detecting that the liquid has been marked, which method comprises: adding to the liquid an additive comprising a plurality of particles in an amount no greater than 1 part weight of particles per 10.sup.6 parts weight liquid, the particles comprising signal means to aid their detection and not being visible in the liquid to the naked eye; sampling a portion of the liquid containing said additive, and detecting the presence of particles in the liquid, with the proviso that said signal means does not consist solely of a nucleic acid tag.Type: GrantFiled: February 27, 1995Date of Patent: July 1, 1997Inventors: James Howard Slater, John Edward Minton
-
Patent number: 5637506Abstract: A method of radiochemical analysis having the steps of providing a solid phase extraction sheet material containing ion-specific sorptive or reactive particles in a porous matrix as carrier for the particles, and providing a fluid including an ion-containing radiochemical analyte, contacting the sheet material with the fluid for a time sufficient for the particles to selectively extract the analyte from the fluid, and analyzing the sheet material in a direct mode for quantitative or qualitative data relating to the radiochemical analyte. Solid phase extraction sheet materials and methods for their preparation are also disclosed.Type: GrantFiled: April 15, 1996Date of Patent: June 10, 1997Assignee: Minnesota Mining and Manufacturing CompanyInventors: Garold L. Goken, Wolfgang H. Strehlow
-
Patent number: 5627036Abstract: Detectably labelled annexines and compositions thereof are disclosed. Also disclosed are methods for diagnosing a disruption or activation of the hemostatic system or a prothrombotic state in an individual suspected of having a hemostatic disorder, by contacting the blood of said individual with an annexine, and detecting whether an annexine-platelet complex is formed.Type: GrantFiled: January 21, 1994Date of Patent: May 6, 1997Assignee: Boehringer Ingelheim International GmbHInventor: Christiaan Reutelingsperger
-
Patent number: 5618734Abstract: For determining 3-deoxyglucosone derivatives which are intermediate metabolites of the Maillard reaction in body fluids such as blood, urine, serum, plasma and the like in gas chromatography/mass spectrometry, .sup.13 C-labelled compounds or .sup.14 C-labelled compounds are useful as an internal standard substance. More specifically, 3-deoxyglucosone derivatives having the formula (I): ##STR1## wherein *C is .sup.13 C or .sup.14 C, X is O or N--OR wherein R is Me, Et or H, and Y is SiMe.sub.3 or SiMe.sub.2 tBu, and their production are provided. The measurement of 3-deoxyglucosone derivatives is useful in diagnosing diseases such as diabetes and diseases complicated with diabetes, including diabetic nephrosis, various renal disorders, renal insufficiency, metabolic diseases of carbohydrate and the like.Type: GrantFiled: March 20, 1995Date of Patent: April 8, 1997Assignee: Kureha Chemical Industry Co., Ltd.Inventors: Toshimitsu Niwa, Koichi Niimura, Minoru Ohara, Sigemi Tomiyama
-
Patent number: 5599716Abstract: A process for the measurement of the level of radioactivity of a solid by contacting the solid with a chemically stable reactant fluid. The reactant fluid is converted by nuclear radiation to a chemically stable product fluid to an extent dependent upon the radioactive content of the solid. The amount of the reactant fluid converted into the product fluid is detected in order to determine the level of radioactivity of the solid.Type: GrantFiled: November 27, 1995Date of Patent: February 4, 1997Assignee: British Nuclear Fuels plcInventor: Robert G. G. Holmes
-
Patent number: 5599541Abstract: Peptide sequence capable of initiating delayed hypersensitivity reactions of different intensity in the presence of living bacteria as opposed to dead bacteria of the Mycobacterium tuberculosis complex. The sequence is characterized in that it comprises no more than 0.5% by weight of tyrosine, phenylalanine, methionine, histidine, arginine and cysteine amino acids. The invention also concerns the diagnostic and therapeutic applications of a peptide or protein comprising said sequence.Type: GrantFiled: October 17, 1994Date of Patent: February 4, 1997Assignee: Institut PasteurInventors: Gilles Marchal, Felix Romain
-
Patent number: 5597548Abstract: Entry of .sup.13 C-enriched acetyl-CoA into the citric acid cycle results in scrambling of .sup.13 C into the various carbon positions of all intermediate pools. The eventual result is that the .sup.13 C resonances of all detectable intermediates or molecules exchanging with those intermediates appear as multiplets due to nearest neighbor spin-spin couplings. Isotopomer analysis of the glutamate .sup.13 C multiplets provides a history of .sup.13 C flow through the cycle pools. Relative substrate utilization and relative anaplerotic flux can be quantitated. A major limitation of the method for in vivo applications is spectral resolution of multi-line resonances required for a complete isotopomer analysis. It is now shown that (.sup.13 C)homonuclear decoupling of the glutamate C3 resonance collapses nine-line C4 and C2 resonances into three line multiplets. These three-line .sup.Type: GrantFiled: July 3, 1995Date of Patent: January 28, 1997Assignee: Board of Regents, The University of Texas SystemInventors: A. Dean Sherry, Piyu Zhao, Craig R. Malloy
-
Patent number: 5561052Abstract: There are disclosed a process for detecting and determining an oxidized lipid in a specimen, which is capable of readily and accurately determining a specimen as containing an oxidized lipid, and a process for forming a water-soluble oxidized lipid having a hydroperoxide group which has specific influence on a living body. A specimen is detected and determined to contain an oxidized lipid by adding a lanthanide shift reagent to a specimen, followed by spectroscopic analysis thereof. An oxidized lipid is formed by adding superoxide dismutase (SOD) and CuSO.sub.4 to (1) an emulsion prepared by dissolving linoleic acid or arachidonic acid in deuterated methyl alcohol and adding the solution to a deuterated phosphate buffer under stirring, or to (2) a low density lipoprotein solution sufficiently dialyzed against an undeuterated phosphate buffer; followed by irradiation with long-wave ultraviolet light.Type: GrantFiled: May 19, 1995Date of Patent: October 1, 1996Inventor: Katsumasa Koike
-
Patent number: 5531964Abstract: In order to reduce liquid effluents and solid waste in an analysis chain receiving liquid samples contained in jugs (16), the proposal is to automate all the operations performed in analysis units or boxes (10a, 10b). Moreover, when the sampling operations necessary for the analyses have been carried out in the analysis units (10a, 10b), the jugs can be automatically dispatched to a recycling apparatus (52).Type: GrantFiled: October 25, 1994Date of Patent: July 2, 1996Assignee: Compagnie Generale Des Matieres NucleairesInventor: Joseph Besnier
-
Patent number: 5532122Abstract: For isotopes decaying by capture of an inner shell electron by the nucleus, coincident emission of X-ray and gamma photons may occur. The X-ray results from the drop of an outer shell electron to fill the S shell. The gamma results from the transition of the excited daughter nucleus to a lower energy state. The invention disclosed is a Coincident Gamma and X-ray Detector (CGXD) which achieves extraordinary background rejection by a synergistic combination of coincident counting and other background suppression measures. Whereas the background registered by single gamma counters is of the order of 20-40 counts per minute, a CGXD optimized for the electron capture radioisotope I.sup.125 has a background of about one count per day.Type: GrantFiled: October 12, 1993Date of Patent: July 2, 1996Assignee: BioTraces, Inc.Inventor: Andrzey K. Drukier
-
Patent number: 5501961Abstract: There is disclosed a method for the determination of a physiological abnormality in a human or animal subject, which method includes determining ion flux across the membrane of epithelial cells taken from the subject, wherein said cells are selected from the group consisting of check epithelial (buccal mucosal) cells, skin dermal epithelial cells and bladder epithelial cells. In one embodiment of the invention, the ion is a sodium ion, and the physiologically abnormality is hypertension or a predisposition towards hypertension.Type: GrantFiled: February 26, 1993Date of Patent: March 26, 1996Assignee: Commonwealth Scientific and Industrial Research OrganisationInventor: Edward J. McMurchie
-
Patent number: 5482865Abstract: A handling and processing apparatus for preparing Oxygen-15 labeled water (H.sub.2 [.sup.15 O]) in injectable form for use in Positron Emission Tomography from preferably H.sub.2 [.sup.15 O] produced by irradiating a flowing gas target of nitrogen and hydrogen. The apparatus includes a collector for receiving and directing a gas containing H.sub.2 [.sup.15 O] gas and impurities, mainly ammonia (NH.sub.3) gas into sterile water to trap the H.sub.2 [.sup.15 O] and form ammonium (NH.sub.4.sup.+) in the sterile water. A device for displacing the sterile water containing H.sub.2 [.sup.15 O] and NH.sub.4.sup.+ through a cation resin removes NH.sub.4.sup.+ from the sterile water. A device for combining the sterile water containing H.sub.2 [.sup.15 O] with a saline solution produces an injectable solution. Preferably, the apparatus includes a device for delivering the solution to a syringe for injection into a patient. Also, disclosed is a method for preparing H.sub.2 [.sup.Type: GrantFiled: June 10, 1994Date of Patent: January 9, 1996Assignee: Associated Universities, Inc.Inventors: Richard A. Ferrieri, David J. Schlyer, David Alexoff
-
Patent number: 5432058Abstract: This invention is a method for measuring the ability of a human to absorb cholesterol. The method uses two different cholesterol tracers, the first injected into the blood stream and the second ingested by the human subject. After a waiting period a blood sample is taken from the human subject and analyzed to determine percent cholesterol absorption based on the actual amounts of the two naturally occurring, metabolically stable cholesterol tracers in the blood. The method of this invention is useful in identifying human subjects as high cholesterol absorbers and thereafter administering therapeutic agents to the subject that inhibit the absorption of cholesterol.Type: GrantFiled: September 30, 1992Date of Patent: July 11, 1995Inventors: Louis G. Lange, III, Richard E. Ostlund, Matthew S. Bosner
-
Patent number: 5427950Abstract: A method of quantitative measurement of a very small amount of low-energy beta radioactivity in a biological sample, a process for preparing samples and a device therefore, which require no large-scaled equipment and no labor for sample preparation, measurement, correction of the measured values and treatment of waste solution after measurement. The method comprises: forming a solid, liquid or liquefied biological sample containing a radioactive substance so as to have a substantially uniform and predetermined thickness; freezing or solidifying the sample and measuring the radioactivity thereof.Type: GrantFiled: January 12, 1993Date of Patent: June 27, 1995Assignee: Kabushiki Kaisha Seitai Kagaku KankyushoInventors: Akiyo Shigematsu, Naomi Motoji, Yasuko Niikura, Yuko Shiina, Yasuhiko Hatori, Mitsunobu Okuyama
-
Patent number: 5413917Abstract: The present invention relates to a method of measuring the contribution of one or more exogenously administered .sup.13 C-labeled substrates to acetyl-CoA. The measurement can be made in a tissue or cell using .sup.13 C NMR without the constraint of metabolic or isotopic steady-state. Furthermore, the method permits the determination even when spectral lines are broad due to B.sub.0 inhomogeneity, thereby opening the way for substrate utilization studies in vivo. The method does not require many of the simplifying assumptions involved in .sup.11 C or .sup.14 C methods, and, since a stable isotope, .sup.13 C, is used a wide variety of compounds with complex labeling patterns may be synthesized and studied.Type: GrantFiled: July 18, 1990Date of Patent: May 9, 1995Assignee: Board of Regents, The University of Texas SystemInventors: Craig R. Malloy, F. Mark H. Jeffrey, A. Dean Sherry
-
Patent number: 5407653Abstract: The present invention relates to methods for detecting the multidrug resistance phenotype in vivo and in vitro. The invention particularly relates to methods of diagnosing the multidrug resistance phenotype by imaging, particularly scintigraphic imaging, in solid tumors in vivo or in tumors and biopsies in vitro. The methods of the present invention allow the diagnosis of multidrug-resistant tumor and other multidrug-resistant phenotypes without invasive surgical methods.Type: GrantFiled: June 26, 1991Date of Patent: April 18, 1995Assignee: Brigham and Women's HospitalInventor: David R. Piwnica-Worms
-
Patent number: 5403574Abstract: The present invention relates to methods for detecting the multidrug resistance phenotype in vivo and in vitro. The invention particularly relates to methods of diagnosing the multidrug resistance phenotype by imaging, particularly scintigraphic imaging, in solid tumors in vivo or in tumors and biopsies in vitro. The methods of the present invention allow the diagnosis of multidrug-resistant tumor and other multidrug-resistant phenotypes without invasive surgical methods. The present invention is also directed to methods of treating multidrug resistant tumors with novel agents that bind to P-glycoprotein. The novel compounds of the present invention are co-administered with a chemotherapeutic agent in order to enhance accumulation of the drug.Type: GrantFiled: June 26, 1992Date of Patent: April 4, 1995Assignee: Brigham and Women's HospitalInventor: David R. Piwnica-Worms
-
Patent number: 5356787Abstract: A method of identifying compounds that modulate the activity of myocardial calcium-independent phospholipase A.sub.2 is disclosed. In a test assay of the method of the invention, myocardial calcium-independent phospholipase A.sub.2 40 kDa catalytic subunit, 85kDa phosphofructokinase isoform, ATP, a substrate and a test compound are combined and the myocardial calcium-independent phospholipase A.sub.2 activity is determined. The level of activity observed in the test assay is compared to the level of activity generated from a control assay which is similar to the test assay but which does not include the test compound. Essentially pure myocardial calcium-independent phospholipase A.sub.2 85kDa phosphofructokinase isoform is also disclosed.Type: GrantFiled: April 23, 1993Date of Patent: October 18, 1994Assignee: Washington UniversityInventor: Richard Gross
-
Patent number: 5354662Abstract: A method for determining the quantity of a connective tissue or muscle tissue breakdown product in a body fluid from an animal includes steps of providing a standard comprising the breakdown product having a label, the standard having a known specific activity, combining the standard and a sample of the body fluid, removing from the combined standard and sample a purified breakdown product fraction containing labelled breakdown product from the standard together with breakdown product from the sample, and measuring the specific radioactivity of the fraction as a measure of the quantity of the breakdown product in the sample.Type: GrantFiled: March 11, 1993Date of Patent: October 11, 1994Assignee: Trustees of Boston UniversityInventors: Phillip J. Stone, Carl Franzblau
-
Patent number: 5346814Abstract: A method of assessing a cell's susceptibility to cell-damaging energy, such as ionizing radiation and heat, is disclosed. The method is based on measurable changes in voltage-dependent potassium channel currents in the cell in response to the energy. Also disclosed is a method for screening drugs which are effective to sensitize a cell to cell-damaging radiation.Type: GrantFiled: October 14, 1992Date of Patent: September 13, 1994Assignee: Board of Trustees of the Leland Stanford Jr. UniversityInventors: George M. Hahn, Alie H. Saad, Amato J. Giaccia
-
Patent number: 5347139Abstract: Using storage phosphor recording media, two exposures are made of a sample containing two target substances tagged with different radiative emitters, for example 32-P and 35-S. The first exposure, image 1, is of the sample directly on the phosphor screen. The second exposure, image 2, is made with the appropriate absorption material between the sample and screen. Both images are captured. By using simultaneous equations isotope contributions of each label can be determined. Quantitative assessment of the contributions of the isotopes, and hence the target substances, are made by calculating isotope efficiencies both with and without the absorption filter.Type: GrantFiled: January 12, 1993Date of Patent: September 13, 1994Assignee: Molecular DynamicsInventors: David L. Barker, Richard F. Johnston, Siobhan C. Pickett